Browsing by Author "Sochor Marek"
Now showing 1 - 12 of 12
Results Per Page
Sort Options
- ItemEarly Integration of Palliative Care into Standard Oncology Care 8211 Benefi ts, Limitations, Barriers and Types of Palliative Care(Česká lékařská společnost J.E. Purkyně, 2018-01-01) Sochor Marek; Sláma O.; Loučka M.
- ItemEstrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.(MDPI AG, 2019-01-01) Vocka Michal; Zimovjanova M; Bielcikova Zuzana; Tesarova Petra; Petruzelka Lubos; Mateju Martin; Krizova Ludmila; Kotlas Jaroslav; Soukupova Jana; Jantarova Marketa; Zemankova Petra; Kleiblova Petra; Novotný Jan; Konopasek Bohuslav; Sochor Marek
- ItemManagement of selected symptoms in oncological palliative care - Constipation and diarrhea(Svoboda, 2017-01-01) Sochor Marek
- ItemManaging Selected Symptoms in Oncology Palliative Care - Cancer Anorexia and Cachexia Syndrome(Svoboda, 2017-01-01) Sochor Marek
- ItemManaging Selected Symptoms in Oncology Palliative Care - Nausea and vomiting(Svoboda, 2017-01-01) Sochor Marek
- ItemModern oncology as the bridge between primary medicine and hospic care(2017-01-01) Sochor Marek
- ItemPacific care in KOC Liberec - first experience after the termination of the project together to the end(2017-01-01) Hrstková Dana; Bartoš Jiří; Sochor Marek
- ItemPalliative care applied together with oncology treatment in patients with advanced tumors(Current Media, s.r.o., 2017-01-01) Sochor Marek; Bartoš Jiří
- ItemPalliative care in oncology(Mladá fronta, 2019-01-01) Sochor Marek; Sláma O.; Závadová Irena
- ItemPrediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer(MDPI AG, 2017-01-01) Bašová Petra; Pešta M.; Sochor Marek; Stopka TomášOncogenic microRNAs (oncomiRs) accumulate in serum due to their increased stability and thus serve as biomarkers in breast cancer (BC) pathogenesis. Four oncogenic microRNAs (miR-155, miR-19a, miR-181b, and miR-24) and one tumor suppressor microRNA (let-7a) were shown to differentiate between high- and low-risk early breast cancer (EBC) and reflect the surgical tumor removal and adjuvant therapy. Here we applied the longitudinal multivariate data analyses to stochastically model the serum levels of each of the oncomiRs using the RT-PCR measurements in the EBC patients (N = 133) that were followed up 4 years after diagnosis. This study identifies that two of the studied oncomiRs, miR-155 and miR-24, are highly predictive of EBC relapse. Furthermore, combining the oncomiR level with Ki-67 expression further specifies the relapse probability. Our data move further the notion that oncomiRs in serum enable not only monitoring of EBC but also are a very useful tool for predicting relapse independently of any other currently analyzed characteristics in EBC patients. Our approach can be translated into medical practice to estimate individual relapse risk of EBC patients.
- ItemPrediction Potential of Serum miR-155 and miR-24 for Relapsing Early Breast Cancer(2018-01-01) Bašová Petra; Pešta M.; Sochor Marek; Stopka Tomáš
- ItemPrevention and treatment of nausea and vomiting induced by chemotherapy(Svoboda, 2018-01-01) Sochor Marek